Semaglutide and Your Heart: SELECT Trial Safety Data Across 17,000 Patients

For patients with obesity and heart disease, a common and reasonable question is: will this weight-loss medication hurt my heart or help it? For decades, the answer for weight-loss drugs was complicated — several were withdrawn from the market precisely because of cardiovascular harm. Semaglutide represents a fundamentally different era. The evidence from the SELECT trial — the largest and most rigorous cardiovascular safety and outcomes study ever conducted for a GLP-1 receptor agonist in a non-diabetic population — does not just confirm that semaglutide is safe for the heart. It shows that semaglutide substantially reduces the risk of heart attack, stroke, and cardiovascular death.

This is not a small finding. It is a landmark result that has changed clinical practice guidelines and the way physicians at programs like Scale Solutions think about the role of GLP-1 medications in comprehensive cardiovascular risk management.

Why Cardiovascular Safety Matters So Much for This Drug Class

The history of weight-loss pharmacotherapy is marked by cardiovascular safety failures. Fen-phen was withdrawn in 1997 after causing valvular heart disease and pulmonary hypertension. Sibutramine was withdrawn in 2010 after an outcomes trial showed increased cardiovascular events. Rimonabant was never approved in the U.S. after showing psychiatric risks. These precedents made the FDA require cardiovascular outcomes trials (CVOTs) for all new diabetes and metabolic medications — a requirement that ultimately produced the extraordinary safety and efficacy data we now have for GLP-1 receptor agonists.

The CVOT requirement was designed to show that new medications are at least non-inferior to placebo on cardiovascular outcomes. Semaglutide did not just meet that bar — it cleared it by a substantial margin.

The SELECT Trial: Design and Population

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), published in the New England Journal of Medicine in December 2023, was a double-blind, randomized, placebo-controlled trial conducted at 804 sites in 41 countries. Participants were adults aged 45 or older with a BMI of 27 or higher and established cardiovascular disease (prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease) — but without type 2 diabetes.

This is an important distinction: SELECT was specifically designed to test semaglutide in patients with cardiovascular disease and obesity but without diabetes. Prior cardiovascular outcome trials for semaglutide (SUSTAIN-6) had studied high-risk diabetic patients. SELECT asked a new and clinically critical question: is the cardiovascular benefit a drug effect, or was it previously driven by glycemic improvement?

A total of 17,604 patients were enrolled — 8,803 assigned to semaglutide 2.4 mg once weekly and 8,801 to placebo. The mean duration of exposure was 34.2 months, and mean follow-up was 39.8 months — more than three years.

Primary Cardiovascular Outcome: 20% Risk Reduction

The primary endpoint was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke — the standard MACE-3 endpoint used in cardiovascular trials. Results were unambiguous:

• MACE occurred in 6.5% of semaglutide patients versus 8.0% of placebo patients
• Hazard ratio: 0.80 (95% CI 0.72–0.90, p < 0.001)
• This represents a 20% relative risk reduction in major adverse cardiovascular events
• The benefit was consistent across all pre-specified subgroups

Breaking down the components as reported by the American College of Cardiology:

• Nonfatal myocardial infarction: 2.7% vs. 3.7% (HR 0.72, 95% CI 0.61–0.85) — a 28% reduction
• All-cause mortality: 4.3% vs. 5.2% (HR 0.81, 95% CI 0.71–0.93) — a 19% reduction
• Heart failure composite (CV death or HF hospitalization): 3.4% vs. 4.1% (HR 0.82, 95% CI 0.71–0.96)

These benefits emerged even in a population where the vast majority of patients were already on evidence-based cardiovascular medications including statins and aspirin — underscoring that semaglutide’s benefit is additive to current standard of care.

SELECT Safety Data: What the Trial Found

A cardiovascular outcomes trial also provides the most rigorous safety assessment available. The SELECT safety data are extensively documented and deserve careful examination:

Overall Adverse Event Profile

Total serious adverse events were actually lower in the semaglutide group than placebo: 33.4% versus 36.4% (p < 0.001). This reflects the broad protective effect of weight loss and cardiovascular risk reduction — patients on semaglutide were less likely to be hospitalized for cardiovascular, renal, and metabolic complications.

Gastrointestinal Events

GI complications were higher in the semaglutide group (10.0% vs. 2.0%). This is consistent with the known GI side effect profile and represents the primary reason for higher discontinuation in the active treatment arm. However, serious GI events were uncommon.

Discontinuation Due to Adverse Events

More semaglutide patients discontinued due to adverse events (16.6% vs. 8.2%), driven predominantly by gastrointestinal intolerance. This is a real consideration but must be weighed against the 20% reduction in MACE in those who continued treatment.

Pancreatitis

Acute pancreatitis: 0.2% semaglutide vs. 0.3% placebo (p = 0.28). Not significantly different — and numerically lower in the semaglutide group.

Kidney Function

Acute kidney failure: 1.9% semaglutide vs. 2.3% placebo (p = 0.13). Not significantly different — with a numerical trend favoring semaglutide, consistent with the FLOW trial kidney outcome data.

Malignancies

Malignant neoplasms: 4.8% semaglutide vs. 4.7% placebo (p = 0.92). Virtually identical rates — no signal of cancer risk.

New Diabetes Onset

One of the most striking secondary findings: 3.5% of semaglutide patients developed diabetes during the trial versus 12.0% of placebo patients (HR 0.27, 95% CI 0.24–0.31). Semaglutide reduced new-onset diabetes by 73% in this high-risk population.

Context from Earlier Trials: SUSTAIN-6 and LEADER

SELECT did not emerge in a vacuum. It built on a body of cardiovascular safety evidence that was already compelling.

The SUSTAIN-6 trial studied semaglutide in 3,297 high-risk patients with type 2 diabetes and found a 26% reduction in MACE over two years, with a favorable safety profile. This was the first evidence that semaglutide’s cardiovascular benefit was real and consistent.

The LEADER trial (NEJM, 2016) studied liraglutide — the original long-acting GLP-1 receptor agonist — in 9,340 high-risk diabetic patients over a median 3.8-year follow-up. LEADER demonstrated a 13% reduction in MACE (HR 0.87), a 22% reduction in cardiovascular death, and a 15% reduction in all-cause mortality. Critically, the liraglutide safety profile showed no increase in pancreatitis (non-significant trend toward lower incidence), no increase in cancer, and no unexpected adverse events.

Together, SUSTAIN-6, LEADER, and SELECT form a consistent and mutually reinforcing body of evidence: GLP-1 receptor agonists reduce cardiovascular risk, and their safety profile is well-characterized and manageable.

The FLOW Trial: Kidney Safety and Benefit

The FLOW trial, published in 2024, studied semaglutide in patients with chronic kidney disease (CKD) and type 2 diabetes — another population with elevated cardiovascular and metabolic risk. Results were landmark: semaglutide reduced the composite primary kidney outcome by 24% and reduced all-cause mortality by 20%. These results extended the safety and benefit profile of semaglutide to a patient population where kidney protection is a major clinical priority.

What This Means for Scale Solutions Patients

For patients at Scale Solutions who have obesity alongside cardiovascular risk factors — hypertension, elevated cholesterol, prior heart attack or stroke, pre-diabetes or diabetes — the SELECT and LEADER data are directly relevant. GLP-1 therapy in these patients is not simply a weight-loss intervention. It is a cardiovascular protective strategy supported by the highest level of clinical evidence.

Dr. Donald L. Gates MD integrates cardiovascular risk assessment into every GLP-1 evaluation, reviewing blood pressure, fasting glucose and HbA1c, lipid panels, and cardiac history. This allows him to identify patients for whom GLP-1 therapy may offer benefits well beyond weight management and to monitor all relevant parameters at follow-up visits. Patients with established cardiovascular disease are precisely the population in whom the SELECT data are most directly applicable.

Learn More About GLP-1 Therapy in Coastal Georgia

The cardiovascular safety and benefit data for semaglutide are among the most robust in the history of metabolic pharmacotherapy. Understanding these data helps patients and their families make confident, informed decisions. Visit our coastal Georgia GLP-1 news page for ongoing updates, or call us to schedule a consultation.

Take the Next Step

Dr. Donald L. Gates MD at Scale Solutions provides comprehensive GLP-1 evaluations for patients in Savannah, Pooler, and Hinesville GA, with close monitoring of cardiovascular risk factors, lab values, and medication response throughout treatment. To schedule your consultation, call (912) 352-7546 or email info@scale-solutions.com.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-1 medications are prescription drugs requiring physician evaluation. The cardiovascular data cited reflect results from specific clinical trial populations; individual patient outcomes vary. Always consult a qualified healthcare provider about your cardiovascular health and medication choices. If you experience chest pain, shortness of breath, or other cardiac symptoms, seek emergency care immediately.

Frequently Asked Questions

Can I take semaglutide if I have had a heart attack?

The SELECT trial specifically enrolled patients with prior heart attack, prior stroke, or symptomatic peripheral arterial disease — and showed a 20% reduction in subsequent MACE events with semaglutide compared to placebo. Patients with a history of heart attack are precisely those for whom the cardiovascular benefit data are most directly relevant. Of course, your cardiologist and primary physician should be part of any treatment decision, and Dr. Gates coordinates care accordingly.

Does semaglutide affect blood pressure or heart rate?

In the SELECT trial, semaglutide reduced systolic blood pressure by an average of 3.8 mmHg compared to 0.5 mmHg in the placebo group at 104 weeks — a meaningful reduction. A small average increase in resting heart rate (approximately 1–4 beats per minute) has been observed across GLP-1 trials. This modest heart rate increase has not translated into adverse cardiovascular outcomes in any large trial, including SELECT.

Is semaglutide approved specifically to prevent heart attacks?

Yes. Following the SELECT trial results, the FDA approved Wegovy (semaglutide 2.4 mg) in March 2024 for the additional indication of reducing the risk of serious cardiovascular events — cardiovascular death, nonfatal heart attack, and nonfatal stroke — in adults with established cardiovascular disease and either obesity or overweight. This makes semaglutide the first weight-management medication to receive an FDA-approved cardiovascular risk reduction indication.

How does semaglutide reduce cardiovascular risk if not through glycemic control?

The SELECT trial enrolled patients without diabetes, proving that the cardiovascular benefit is not solely mediated by blood sugar improvement. The mechanisms appear to be multifactorial: weight loss reduces cardiac workload and blood pressure, anti-inflammatory effects of GLP-1 receptor agonism may reduce atherosclerotic plaque progression, improvements in lipid profiles contribute, and direct cardiac effects of GLP-1 receptors on the myocardium and vasculature may play a role as well.

Should patients with heart failure use semaglutide?

The SELECT trial included a subgroup of patients with heart failure (both preserved and reduced ejection fraction), and the cardiovascular benefit of semaglutide was consistent across these subgroups. A separate dedicated heart failure trial (STEP-HFpEF) also demonstrated benefits of semaglutide in patients with heart failure with preserved ejection fraction. Patients with heart failure should discuss GLP-1 therapy with their cardiologist and bariatric physician, as individual circumstances vary. Dr. Gates coordinates with specialists when managing patients with complex cardiac histories.